Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients.

about

Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent

P2860

Q57191759-272FD010-C49A-41E1-B46A-107B9D51ED9A

P2860

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients.

Item

http://www.wikidata.org/entity/Q53835921

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@en

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@nl

type

Item

label

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@en

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@nl

prefLabel

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@en

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@nl

P1476

Positive Effect of Liposomal A ...... s in Cystic Fibrosis Patients.

@en

P2093

Catherine Guinet

http://www.w3.org/2001/XMLSchema#string

Delphine Trioleyre

http://www.w3.org/2001/XMLSchema#string

Nicolas Martocq

http://www.w3.org/2001/XMLSchema#string

Raphael Chiron

http://www.w3.org/2001/XMLSchema#string

Thomas Daniel

http://www.w3.org/2001/XMLSchema#string

P2860

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.

Rifabutin Is Active against Mycobacterium abscessus Complex.

Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi

Environmental risks for nontuberculous mycobacteria. Individual exposures and climatic factors in the cystic fibrosis population.

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Mycobacterium abscessus infection in cystic fibrosis: molecular typing and clinical outcomes.

Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin

Pulmonary Disease Caused by Non-Tuberculous Mycobacteria.

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

P304

ofy034

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/OFID/OFY034

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sylvain Godreuil

D Caimmi

P577

2018-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29564361

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

5846290

http://www.w3.org/2001/XMLSchema#string

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients.

about

P2860

P2860

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932